Orexo starts patient dosing in Phase III study of opioid dependence drug

Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news